Manufacturing Bispecific Antibodies:
Development & Scale-Up
About this webinar
Bispecific antibodies have emerged as a rapidly growing biologic modality that can engage two distinct biological targets within a single molecule. Their unique mechanisms of action have created new opportunities in oncology, immunology and other therapeutic areas, enabling treatment strategies that may not be achievable with traditional monoclonal antibodies. However, the same structural complexity that drives their therapeutic potential also introduces significant development and manufacturing challenges. This webinar explores the critical considerations involved in developing and manufacturing bispecific antibodies, from early-stage process development through commercial scale-up.
The featured speaker will examine how antibody design influences manufacturability, why correct heavy and light chain pairing is essential and the strategies development teams use to promote formation of the desired molecular structure while minimizing product variants.
The session will also examine the role of cell line development, analytical characterization and process optimization in supporting product quality and consistency. Focus will be placed on downstream purification challenges, including the removal of mispaired and incomplete antibody species and the design of chromatography-based purification workflows capable of achieving clinical and commercial purity requirements.
As bispecific antibody programs advance toward larger manufacturing scales, maintaining product consistency becomes increasingly important. The webinar will discuss how process parameters can influence variant distribution and how robust process characterization helps ensure reliable performance during scale-up. The featured speaker will discuss a real-world example of how purification strategies were optimized to improve product purity and support successful transition into clinical manufacturing.
Register for this webinar to learn how bispecific antibodies can be developed and manufactured to address purification, product consistency and scale-up challenges.
Who should attend
This webinar will appeal to professionals involved in bispecific antibody development and manufacturing, including:
- MSAT (Manufacturing Science & Technology)
- Process Development Scientists
- Upstream and Downstream Development
- Bioprocess Engineers
- CMC and Technical Operations leaders
- Analytical Development Scientists
- Manufacturing and Operations professionals
- Biologics Development leaders
- Quality and Regulatory professionals
- Program and Project Managers supporting biologic development
What you will learn
Attendees will:
- Understand the unique development and manufacturing challenges associated with bispecific antibodies, including molecular assembly and product heterogeneity
- Learn approaches for optimizing cell line development, analytical characterization and process design to support product quality and consistency
- Explore purification strategies used to remove mispaired antibody species while maintaining acceptable process yields
- Discover scale-up considerations and best practices for advancing bispecific antibody programs toward clinical and commercial manufacturing
Featured Speakers
Dave Briggs, PhD
Dave Briggs, PhD, brings extensive experience in biopharmaceutical manufacturing, spanning purification R&D, downstream process development, manufacturing operations, process validation and continued process verification. Throughout his career, he has supported the development, transfer, validation and commercialization of biologic processes, with a focus on translating scientific understanding into robust, scalable and compliant manufacturing solutions.
As a Principal Scientist in Manufacturing Science and Technology (MSAT), Late Stage/Commercial, at Avid Bioservices, Dave leads cross-functional initiatives supporting process performance qualification, lifecycle management, process monitoring and continuous improvement of commercial manufacturing processes. He is recognized for applying data-driven approaches to enhance process robustness, ensure regulatory compliance and drive operational excellence across the product lifecycle.
Dave holds a PhD in Molecular and Cellular Biology from the University of Arizona and a BSc in Microbiology from Brigham Young University. His expertise spans downstream processing, chromatography, technology transfer, process validation, manufacturing science and continued process verification, with a passion for transforming complex technical challenges into practical solutions that enable reliable and efficient biologics manufacturing.
Partner for this event
Avid Bioservices
Avid Bioservices is a leading U.S.-based mammalian cell culture contract development and manufacturing organization providing integrated process development, analytical development, and CGMP biologics manufacturing from DNA to IND to commercial supply.
A trusted partner for biopharmaceutical innovators worldwide, Avid combines manufacturing, operational discipline, and a transparent partnership model to reduce risk and simplify execution. Agility, quality, proven ability to navigate complex global regulatory landscapes and a steadfast FDA record make Avid the best choice for a U.S.-based biologics CDMO. From DNA to IND to Commercial, Avid is the U.S.-based biologics CDMO partner for every stage. With you, every molecule of the way.